The opportunistic low ball takeover scenario has a negligible...

The opportunistic low ball takeover scenario has a negligible chance of success for one very simple reason:

We have a product that (extremely likely) does things that EVERYBODY covets and absolutely NOBODY has.

And we have a conga line of Mega Suitors.

If Acadia offers up $35, well Merck won’t blink at offering $40.

Pfizer will say hang it, let’s do $50.

BMS won’t want to left behind, let’s do $55.

Well Novartis won’t blink - $60 please.

Eli Lilly says that’s pocket change for us compared to the potential upside; $70 on the table…

Plenty of others too - you get the drift….

Bottom line for me is that Neuren will be a jostling, rousing Auction.

Everyone will be watching the competition and no one will ultimately want to miss out on the Big Prize.